Results 81 to 90 of about 58,036 (310)
, 2000 Chronic treatment with L-DOPA induces dyskinesia in patients with Parkinson's disease (PD) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys, but is not thought to do so in normal humans or primates.
Pearce, R K B +7 more
core +1 more source
Topological Materials and Related Applications
Advanced Electronic Materials, EarlyView.This review covers topological materials—including topological insulators, quantum valley Hall and quantum spin Hall insulators, and topological Weyl and Dirac semimetals—as well as their most recent advancements in fields such as spintronics, electronics, photonics, thermoelectrics, and catalysis.
Carlo Grazianetti +9 more
wiley +1 more source
, 2015 (A) Time-course of serum L-DOPA levels after last L-DOPA administration at dose 5 mg/kg (day 10) with co-injection of 1.25 mg/kg carbidopa (n = 5 per AAV2-hAADC or AAV2-GFP group) and without carbidopa co-injection (n = 5 per AAV2-hAADC or AAV2-GFP group)
Nitasha Sharma (720396) +4 more
core +1 more source
Animal Models and Experimental Medicine, EarlyView.Gut microbiota from patients with type 2 diabetes induced early diabetes‐like phenotypes in germ‐free mice, including progressive glucose intolerance and mild renal injury. Longitudinal profiling revealed persistent dysbiosis preceding stable metabolic dysfunction, with coordinated fecal and plasma metabolite alterations and a prominent L‐Dopa ...
Jianghao Feng +6 more
wiley +1 more source
Enhancement of L-Dopa Incorporation into Melanoma by Dopa Decarboxylase Inhibition
Journal of Investigative Dermatology, 1978 Melanoma cells possess a special biochemical pathway for the conversion of L-dopa to melanin. Selective incorparation of exogenous L-dopa into melanoma cells in vivo has been limited by extensive decarboxylation to dopamine. Pretreatment of animals bearing the S-91 Cloudman or ACI melanomas with Ro4-4602, a potent dopa decarboxylase inhibitor limited ...
Wick, Michael M. +2 more
openaire +2 more sources
, 2014 Striatal astrocytes were treated with methyl-L-DOPA (200 µM) for 4 h or 8 h (filled bar). Furthermore, astrocytes pre-treated with methyl-L-DOPA for 8 h were incubated in fresh medium for 1 h or 4 h (gray bar).
Masato Asanuma (420841) +4 more
core +1 more source
Advanced NanoBiomed Research, EarlyView.Key demographic, biological, and material considerations that drive the need for advanced injectable bone cement technologies. Injectable bone cements (IBCs) are widely used in orthopaedic and craniofacial applications due to their minimally invasive delivery and ability to provide early mechanical stabilisation.
Frank Fei +2 more
wiley +1 more source
Neurobiology of Disease, 2013 The serotonin system has recently emerged as an important player in the appearance of l-DOPA-induced dyskinesia (LID) in experimental models of Parkinson's disease, as it provides an unregulated source of l-DOPA-derived dopamine release in the dopamine ...
Elisabetta Tronci +6 more
doaj +1 more source
Molecular basis of L-DOPA-induced dyskinesia : studies on striatal signaling
, 2009 Parkinson s disease (PD) is a neurological disorder characterized by tremor, rigidity and bradykinesia. PD is caused by selective degeneration of the dopaminergic neurons, which originate in the substantia nigra pars compacta (SNc) and project to the ...
Emanuela Santini (362343)
core
Biomolecules3,4-Dihydroxy-L-phenylalanine (DOPA) is a promising noncanonical amino acid (ncAA) that introduces novel catechol chemical features into proteins, expanding their functional potential.
Youhui Yang +3 more
doaj +1 more source